CDP870

certolizumab pegol · UCB S.A.

Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for CDP870, covering 2012-08-06 to 2022-06-10. Get the full timeline:

Most recent: Clinical Trial Update: Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis [Phase 3]